

**Green et al.:**

**Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction – a Danish nationwide population based cohort study**

**Supplementary tables**

**Supplementary Table 1** Baseline demographic and clinical characteristics for the total first-time MI population (2009-2012, incl.)

|   | Patients with PCI (N=14852, 52%) |                       |                      |                     |                   | Patients without PCI (N=13597, 48%) |                       |                      |                   |                   |
|---|----------------------------------|-----------------------|----------------------|---------------------|-------------------|-------------------------------------|-----------------------|----------------------|-------------------|-------------------|
|   | All patients<br>n=14852          | Clopidogrel<br>n=9140 | Ticagrelor<br>n=2991 | Prasugrel<br>n=1030 | No DAPT<br>n=1691 | All patients<br>n=13597             | Clopidogrel<br>n=5513 | Ticagrelor<br>n=1221 | Prasugrel<br>n=62 | No DAPT<br>n=6801 |
| Age [median (IQR)]                          | 65 (55 - 74)                     | 65 (56 - 74)          | 65 (55 - 73)         | 60 (51 - 67)        | 67 (58 - 75)      | 74 (63 - 83)                        | 74 (64 - 83)          | 71 (61 - 80)         | 60 (49 - 67)      | 74 (62 - 83)      |
| Males                                       | 10,848 (73.0%)                   | 6,642 (72.7%)         | 2,161 (72.3%)        | 833 (80.9%)         | 1,212 (71.7%)     | 7,358 (54.1%)                       | 2,985 (54.1%)         | 662 (54.2%)          | 42 (67.7%)        | 3,669 (53.9%)     |
| <b>Type of hospital (at index MI event)</b> |                                  |                       |                      |                     |                   |                                     |                       |                      |                   |                   |
| Local hospital                              | 3,797 (25.6%)                    | 2,478 (27.1%)         | 707 (23.6%)          | 132 (12.8%)         | 480 (28.4%)       | 5,490 (40.4%)                       | 2,074 (37.6%)         | 404 (33.1%)          | 13 (21.0%)        | 2,999 (44.1%)     |
| Main regional hospital                      | 5,463 (36.8%)                    | 3,165 (34.6%)         | 1,331 (44.5%)        | 431 (41.8%)         | 536 (31.7%)       | 4,647 (34.2%)                       | 2,083 (37.8%)         | 564 (46.2%)          | 24 (38.7%)        | 1,976 (29.1%)     |
| Tertiary cardiac hospital                   | 5,592 (37.7%)                    | 3,497 (38.3%)         | 953 (31.9%)          | 467 (45.3%)         | 675 (39.9%)       | 3,460 (25.4%)                       | 1,356 (24.6%)         | 253 (20.7%)          | 25 (40.3%)        | 1,826 (26.8%)     |
| <b>Procedures (at index event)</b>          |                                  |                       |                      |                     |                   |                                     |                       |                      |                   |                   |
| CABG  | 328 (2.2%)                       | 177 (1.9%)            | 28 (0.9%)            | (n<=5)              | 119 (7.0%)        | 1,727 (12.7%)                       | 660 (12.0%)           | 165 (13.5%)          | (n<=5)            | 898 (13.2%)       |
| Angiography                                 | 14,626 (98.5%)                   | 9,009 (98.6%)         | 2,946 (98.5%)        | 1,012 (98.3%)       | 1,659 (98.1%)     | 7,330 (53.9%)                       | 3,138 (56.9%)         | 865 (70.8%)          | 36 (58.1%)        | 3,291 (48.4%)     |
| <b>Previous diagnoses</b>                   |                                  |                       |                      |                     |                   |                                     |                       |                      |                   |                   |
| Heart failure                               | 358 (2.4%)                       | 211 (2.3%)            | 49 (1.6%)            | 12 (1.2%)           | 86 (5.1%)         | 1,185 (8.7%)                        | 459 (8.3%)            | 53 (4.3%)            | (n<=5)            | 671 (9.9%)        |
| Ischaemic heart disease                     | 985 (6.6%)                       | 550 (6.0%)            | 152 (5.1%)           | 46 (4.5%)           | 237 (14.0%)       | 1,740 (12.8%)                       | 658 (11.9%)           | 131 (10.7%)          | 11 (17.7%)        | 940 (13.8%)       |
| Unstable angina                             | 208 (1.4%)                       | 117 (1.3%)            | 34 (1.1%)            | 11 (1.1%)           | 46 (2.7%)         | 365 (2.7%)                          | 132 (2.4%)            | 15 (1.2%)            | 5 (8.1%)          | 213 (3.1%)        |
| Peripheral arterial disease                 | 442 (3.0%)                       | 263 (2.9%)            | 67 (2.2%)            | 21 (2.0%)           | 91 (5.4%)         | 945 (7.0%)                          | 397 (7.2%)            | 73 (6.0%)            | (n<=5)            | 474 (7.0%)        |
| Stroke total                                | 520 (3.5%)                       | 315 (3.4%)            | 89 (3.0%)            | 8 (0.8%)            | 108 (6.4%)        | 1,194 (8.8%)                        | 527 (9.6%)            | 65 (5.3%)            | 0 (0.0%)          | 602 (8.9%)        |
| Non-ischaemic stroke                        | 38 (0.3%)                        | 26 (0.3%)             | 6 (0.2%)             | 0 (0.0%)            | 6 (0.4%)          | 74 (0.5%)                           | 25 (0.5%)             | 5 (0.4%)             | 0 (0.0%)          | 44 (0.6%)         |
| Ischaemic stroke                            | 495 (3.3%)                       | 298 (3.3%)            | 85 (2.8%)            | 8 (0.8%)            | 104 (6.2%)        | 1,153 (8.5%)                        | 512 (9.3%)            | 62 (5.1%)            | 0 (0.0%)          | 579 (8.5%)        |
| Atrial fibrillation                         | 539 (3.6%)                       | 301 (3.3%)            | 80 (2.7%)            | 14 (1.4%)           | 144 (8.5%)        | 1,426 (10.5%)                       | 445 (8.1%)            | 71 (5.8%)            | 0 (0.0%)          | 910 (13.4%)       |
| Chronic renal dysfunction                   | 95 (0.6%)                        | 52 (0.6%)             | 17 (0.6%)            | (n<=5)              | 24 (1.4%)         | 158 (1.2%)                          | 57 (1.0%)             | 5 (0.4%)             | (n<=5)            | 94 (1.4%)         |
| Diabetes mellitus                           | 1,871 (12.6%)                    | 1,117 (12.2%)         | 374 (12.5%)          | 106 (10.3%)         | 274 (16.2%)       | 2,513 (18.5%)                       | 1,048 (19.0%)         | 200 (16.4%)          | 9 (14.5%)         | 1,256 (18.5%)     |
| Major bleeding                              | 359 (2.4%)                       | 226 (2.5%)            | 59 (2.0%)            | 12 (1.2%)           | 62 (3.7%)         | 713 (5.2%)                          | 248 (4.5%)            | 41 (3.4%)            | (n<=5)            | 423 (6.2%)        |
| Liver disease                               | 21 (0.1%)                        | 10 (0.1%)             | (n<=5)               | (n<=5)              | 7 (0.4%)          | 23 (0.2%)                           | 5 (0.1%)              | (n<=5)               | 0 (0.0%)          | 17 (0.2%)         |
| Coagulation disorders                       | 45 (0.3%)                        | 28 (0.3%)             | 5 (0.2%)             | 0 (0.0%)            | 12 (0.7%)         | 81 (0.6%)                           | 18 (0.3%)             | (n<=5)               | 0 (0.0%)          | 60 (0.9%)         |
| Cancer                                      | 924 (6.2%)                       | 556 (6.1%)            | 179 (6.0%)           | 49 (4.8%)           | 140 (8.3%)        | 1,330 (9.8%)                        | 490 (8.9%)            | 116 (9.5%)           | 0 (0.0%)          | 724 (10.6%)       |
| <b>Drug use at discharge</b>                |                                  |                       |                      |                     |                   |                                     |                       |                      |                   |                   |
| Total number of drugs [median (IQR)]        | 3 (1 - 6)                        | 3 (1 - 6)             | 3 (1 - 6)            | 2 (0 - 4)           | 4 (2 - 8)         | 6 (3 - 10)                          | 6 (3 - 10)            | 5 (2 - 9)            | 4 (1 - 7)         | 6 (3 - 11)        |
| ACE-inhibitors and ARB                      | 8,140 (54.8%)                    | 5,106 (55.9%)         | 1,536 (51.4%)        | 538 (52.2%)         | 960 (56.8%)       | 7,610 (56.0%)                       | 3,240 (58.8%)         | 668 (54.7%)          | 36 (58.1%)        | 3,666 (53.9%)     |

|  |                |                |                |                |               |                |                |                |             |               |
|--|----------------|----------------|----------------|----------------|---------------|----------------|----------------|----------------|-------------|---------------|
| Acetyl salicylic acid  | 14,109 (95.0%) | 9,140 (100.0%) | 2,991 (100.0%) | 1,030 (100.0%) | 948 (56.1%)   | 11,166 (82.1%) | 5,513 (100.0%) | 1,221 (100.0%) | 62 (100.0%) | 4,370 (64.3%) |
| Betablocker  | 13,065 (88.0%) | 8,093 (88.5%)  | 2,626 (87.8%)  | 948 (92.0%)    | 1,398 (82.7%) | 9,719 (71.5%)  | 4,450 (80.7%)  | 997 (81.7%)    | 52 (83.9%)  | 4,220 (62.0%) |
| Calcium-channel blocker  | 3,259 (21.9%)  | 1,987 (21.7%)  | 646 (21.6%)    | 161 (15.6%)    | 465 (27.5%)   | 4,310 (31.7%)  | 1,763 (32.0%)  | 391 (32.0%)    | 24 (38.7%)  | 2,132 (31.3%) |
| Oral antidiabetics and insulin                                     | 1,728 (11.6%)  | 1,034 (11.3%)  | 355 (11.9%)    | 95 (9.2%)      | 244 (14.4%)   | 2,235 (16.4%)  | 952 (17.3%)    | 189 (15.5%)    | 9 (14.5%)   | 1,085 (16.0%) |
| Proton pump inhibitors   | 4,092 (27.6%)  | 2,433 (26.6%)  | 932 (31.2%)    | 204 (19.8%)    | 523 (30.9%)   | 5,151 (37.9%)  | 1,977 (35.9%)  | 429 (35.1%)    | 19 (30.6%)  | 2,726 (40.1%) |
| Statins  | 14,131 (95.1%) | 8,748 (95.7%)  | 2,894 (96.8%)  | 1,011 (98.2%)  | 1,478 (87.4%) | 9,599 (70.6%)  | 4,531 (82.2%)  | 1,062 (87.0%)  | 57 (91.9%)  | 3,949 (58.1%) |
| Anticoagulant  | 913 (6.1%)     | 488 (5.3%)     | 127 (4.2%)     | 35 (3.4%)      | 263 (15.6%)   | 1,742 (12.8%)  | 395 (7.2%)     | 92 (7.5%)      | (n<=5)      | 1,254 (18.4%) |
| NSAIDs   | 2,562 (17.3%)  | 1,606 (17.6%)  | 506 (16.9%)    | 152 (14.8%)    | 298 (17.6%)   | 2,506 (18.4%)  | 1,005 (18.2%)  | 226 (18.5%)    | 12 (19.4%)  | 1,263 (18.6%) |
| <b>Time until P2Y<sub>12</sub> antagonist prescription claimed</b> |                |                |                |                |               |                |                |                |             |               |
| Prior to MI  | 564 (3.8%)     | 349 (3.8%)     | 103 (3.4%)     | 36 (3.5%)      | 76 (4.5%)     | 704 (5.2%)     | 449 (8.1%)     | 60 (4.9%)      | 6 (9.7%)    | 189 (2.8%)    |
| 1-7 days   | 13,083 (88.1%) | 8,512 (93.1%)  | 2,838 (94.9%)  | 977 (94.9%)    | 756 (44.7%)   | 6,589 (48.5%)  | 4,724 (85.7%)  | 1,114 (91.2%)  | 52 (83.9%)  | 699 (10.3%)   |
| 8-14 days  | 141 (0.9%)     | 94 (1.0%)      | 20 (0.7%)      | 11 (1.1%)      | 16 (0.9%)     | 205 (1.5%)     | 160 (2.9%)     | 25 (2.0%)      | 0 (0.0%)    | 20 (0.3%)     |
| 15-30 days   | 246 (1.7%)     | 185 (2.0%)     | 30 (1.0%)      | 6 (0.6%)       | 25 (1.5%)     | 238 (1.8%)     | 180 (3.3%)     | 22 (1.8%)      | (n<=5)      | 32 (0.5%)     |
| No prescription  | 818 (5.5%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 818 (48.4%)   | 5,861 (43.1%)  | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)    | 5,861 (86.2%) |

Numbers in parentheses are percentages of total number of patients in the group; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention; IQR, interquartile range; Local hospital, hospital without catheterization laboratory; Main regional hospital, hospital with catheterization laboratory; Tertiary cardiac hospital, university hospital with catheterization laboratory; CABG, coronary artery bypass graft; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs.

**Supplementary Table 2** Baseline demographic and clinical characteristics for the 2010 first-time MI population

|   | Patients with PCI (N=3673, 49%) |                       |                   |                   |                  | Patients without PCI (N=3754, 51%) |                       |                   |                  |                   |
|---|---------------------------------|-----------------------|-------------------|-------------------|------------------|------------------------------------|-----------------------|-------------------|------------------|-------------------|
|   | All patients<br>n=3673          | Clopidogrel<br>n=3127 | Ticagrelor<br>n=0 | Prasugrel<br>n=79 | No DAPT<br>n=467 | All patients<br>n=3754             | Clopidogrel<br>n=1830 | Ticagrelor<br>n=0 | Prasugrel<br>n=5 | No DAPT<br>n=1919 |
| Age [median (IQR)]                          | 65 (56 - 73)                    | 64 (56 - 73)          | . ( . - . )       | 61 (53 - 72)      | 66 (57 - 74)     | 73 (62 - 83)                       | 73 (63 - 83)          | . ( . - . )       | 62 (61 - 65)     | 73 (61 - 83)      |
| Males                                       | 2,682 (73.0%)                   | 2,275 (72.8%)         | 0 (.)             | 66 (83.5%)        | 341 (73.0%)      | 2,002 (53.3%)                      | 996 (54.4%)           | 0 (.)             | (n<=5)           | 1,002 (52.2%)     |
| <b>Type of hospital (at index MI event)</b> |                                 |                       |                   |                   |                  |                                    |                       |                   |                  |                   |
| Local hospital                              | 915 (24.9%)                     | 792 (25.3%)           | 0 (.)             | 10 (12.7%)        | 113 (24.2%)      | 1,502 (40.0%)                      | 642 (35.1%)           | 0 (.)             | (n<=5)           | 857 (44.7%)       |
| Main regional hospital                      | 1,337 (36.4%)                   | 1,178 (37.7%)         | 0 (.)             | 21 (26.6%)        | 138 (29.6%)      | 1,280 (34.1%)                      | 730 (39.9%)           | 0 (.)             | (n<=5)           | 549 (28.6%)       |
| Tertiary cardiac hospital                   | 1,421 (38.7%)                   | 1,157 (37.0%)         | 0 (.)             | 48 (60.8%)        | 216 (46.3%)      | 972 (25.9%)                        | 458 (25.0%)           | 0 (.)             | (n<=5)           | 513 (26.7%)       |
| <b>Procedures (at index event)</b>          |                                 |                       |                   |                   |                  |                                    |                       |                   |                  |                   |
| CABG  | 73 (2.0%)                       | 43 (1.4%)             | 0 (.)             | 0 (0.0%)          | 30 (6.4%)        | 417 (11.1%)                        | 217 (11.9%)           | 0 (.)             | 0 (0.0%)         | 200 (10.4%)       |
| Angiography                                 | 3,620 (98.6%)                   | 3,084 (98.6%)         | 0 (.)             | 76 (96.2%)        | 460 (98.5%)      | 1,983 (52.8%)                      | 1,094 (59.8%)         | 0 (.)             | (n<=5)           | 888 (46.3%)       |
| <b>Previous diagnoses</b>                   |                                 |                       |                   |                   |                  |                                    |                       |                   |                  |                   |
| Heart failure                               | 89 (2.4%)                       | 68 (2.2%)             | 0 (.)             | (n<=5)            | 20 (4.3%)        | 332 (8.8%)                         | 136 (7.4%)            | 0 (.)             | 0 (0.0%)         | 196 (10.2%)       |
| Ischaemic heart disease                     | 244 (6.6%)                      | 176 (5.6%)            | 0 (.)             | 9 (11.4%)         | 59 (12.6%)       | 466 (12.4%)                        | 208 (11.4%)           | 0 (.)             | (n<=5)           | 257 (13.4%)       |
| Unstable angina                             | 51 (1.4%)                       | 35 (1.1%)             | 0 (.)             | (n<=5)            | 13 (2.8%)        | 117 (3.1%)                         | 41 (2.2%)             | 0 (.)             | 0 (0.0%)         | 76 (4.0%)         |
| Peripheral arterial disease                 | 110 (3.0%)                      | 90 (2.9%)             | 0 (.)             | (n<=5)            | 19 (4.1%)        | 262 (7.0%)                         | 126 (6.9%)            | 0 (.)             | 0 (0.0%)         | 136 (7.1%)        |
| Stroke total                                | 133 (3.6%)                      | 106 (3.4%)            | 0 (.)             | 0 (0.0%)          | 27 (5.8%)        | 346 (9.2%)                         | 162 (8.9%)            | 0 (.)             | 0 (0.0%)         | 184 (9.6%)        |
| Non-ischaemic stroke                        | 9 (0.2%)                        | 7 (0.2%)              | 0 (.)             | 0 (0.0%)          | (n<=5)           | 24 (0.6%)                          | 9 (0.5%)              | 0 (.)             | 0 (0.0%)         | 15 (0.8%)         |
| Ischaemic stroke                            | 127 (3.5%)                      | 101 (3.2%)            | 0 (.)             | 0 (0.0%)          | 26 (5.6%)        | 332 (8.8%)                         | 156 (8.5%)            | 0 (.)             | 0 (0.0%)         | 176 (9.2%)        |
| Atrial fibrillation                         | 122 (3.3%)                      | 93 (3.0%)             | 0 (.)             | (n<=5)            | 27 (5.8%)        | 389 (10.4%)                        | 137 (7.5%)            | 0 (.)             | 0 (0.0%)         | 252 (13.1%)       |
| Chronic renal dysfunction                   | 24 (0.7%)                       | 21 (0.7%)             | 0 (.)             | 0 (0.0%)          | (n<=5)           | 39 (1.0%)                          | 17 (0.9%)             | 0 (.)             | 0 (0.0%)         | 22 (1.1%)         |
| Diabetes mellitus                           | 465 (12.7%)                     | 392 (12.5%)           | 0 (.)             | 13 (16.5%)        | 60 (12.8%)       | 697 (18.6%)                        | 336 (18.4%)           | 0 (.)             | 0 (0.0%)         | 361 (18.8%)       |
| Major bleeding                              | 88 (2.4%)                       | 69 (2.2%)             | 0 (.)             | (n<=5)            | 17 (3.6%)        | 205 (5.5%)                         | 88 (4.8%)             | 0 (.)             | (n<=5)           | 116 (6.0%)        |
| Liver disease                               | 6 (0.2%)                        | (n<=5)                | 0 (.)             | 0 (0.0%)          | (n<=5)           | 5 (0.1%)                           | (n<=5)                | 0 (.)             | 0 (0.0%)         | (n<=5)            |
| Coagulation disorders                       | 12 (0.3%)                       | 10 (0.3%)             | 0 (.)             | 0 (0.0%)          | (n<=5)           | 26 (0.7%)                          | 9 (0.5%)              | 0 (.)             | 0 (0.0%)         | 17 (0.9%)         |
| Cancer                                      | 224 (6.1%)                      | 188 (6.0%)            | 0 (.)             | (n<=5)            | 33 (7.1%)        | 341 (9.1%)                         | 153 (8.4%)            | 0 (.)             | 0 (0.0%)         | 188 (9.8%)        |
| <b>Drug use at discharge</b>                |                                 |                       |                   |                   |                  |                                    |                       |                   |                  |                   |
| Total number of drugs [median (IQR)]        | 3 (1 - 6)                       | 3 (1 - 6)             | . ( . - . )       | 4 (1 - 7)         | 4 (1 - 8)        | 6 (3 - 10)                         | 6 (3 - 10)            | . ( . - . )       | 3 (2 - 4)        | 6 (3 - 11)        |
| ACE-inhibitors and ARB                      | 2,051 (55.8%)                   | 1,737 (55.5%)         | 0 (.)             | 50 (63.3%)        | 264 (56.5%)      | 2,075 (55.3%)                      | 1,067 (58.3%)         | 0 (.)             | (n<=5)           | 1,004 (52.3%)     |
| Acetyl salicylic acid                       | 3,485 (94.9%)                   | 3,127 (100.0%)        | 0 (.)             | 79 (100.0%)       | 279 (59.7%)      | 3,044 (81.1%)                      | 1,830 (100.0%)        | 0 (.)             | 5 (100.0%)       | 1,209 (63.0%)     |
| Betablocker                                 | 3,239 (88.2%)                   | 2,774 (88.7%)         | 0 (.)             | 66 (83.5%)        | 399 (85.4%)      | 2,659 (70.8%)                      | 1,496 (81.7%)         | 0 (.)             | 5 (100.0%)       | 1,158 (60.3%)     |
| Calcium-channel blocker                     | 784 (21.3%)                     | 656 (21.0%)           | 0 (.)             | 23 (29.1%)        | 105 (22.5%)      | 1,180 (31.4%)                      | 589 (32.2%)           | 0 (.)             | (n<=5)           | 590 (30.7%)       |

|  |               |               |       |            |             |               |               |       |            |               |
|--|---------------|---------------|-------|------------|-------------|---------------|---------------|-------|------------|---------------|
| Oral antidiabetics and insulin                                     | 428 (11.7%)   | 362 (11.6%)   | 0 (%) | 11 (13.9%) | 55 (11.8%)  | 611 (16.3%)   | 302 (16.5%)   | 0 (%) | 0 (0.0%)   | 309 (16.1%)   |
| Proton pump inhibitors   | 912 (24.8%)   | 755 (24.1%)   | 0 (%) | 23 (29.1%) | 134 (28.7%) | 1,340 (35.7%) | 613 (33.5%)   | 0 (%) | (n<=5)     | 724 (37.7%)   |
| Statins  | 3,517 (95.8%) | 3,012 (96.3%) | 0 (%) | 77 (97.5%) | 428 (91.6%) | 2,596 (69.2%) | 1,514 (82.7%) | 0 (%) | 5 (100.0%) | 1,077 (56.1%) |
| Anticoagulant  | 189 (5.1%)    | 130 (4.2%)    | 0 (%) | (n<=5)     | 55 (11.8%)  | 454 (12.1%)   | 119 (6.5%)    | 0 (%) | 0 (0.0%)   | 335 (17.5%)   |
| NSAIDs   | 677 (18.4%)   | 576 (18.4%)   | 0 (%) | 9 (11.4%)  | 92 (19.7%)  | 734 (19.6%)   | 369 (20.2%)   | 0 (%) | 0 (0.0%)   | 365 (19.0%)   |
| <b>Time until P2Y<sub>12</sub> antagonist prescription claimed</b> |               |               |       |            |             |               |               |       |            |               |
| Prior to MI  | 131 (3.6%)    | 108 (3.5%)    | 0 (%) | (n<=5)     | 19 (4.1%)   | 139 (3.7%)    | 101 (5.5%)    | 0 (%) | 0 (0.0%)   | 38 (2.0%)     |
| 1-7 days   | 3,207 (87.3%) | 2,948 (94.3%) | 0 (%) | 72 (91.1%) | 187 (40.0%) | 1,814 (48.3%) | 1,636 (89.4%) | 0 (%) | (n<=5)     | 174 (9.1%)    |
| 8-14 days  | 29 (0.8%)     | 25 (0.8%)     | 0 (%) | (n<=5)     | (n<=5)      | 52 (1.4%)     | 44 (2.4%)     | 0 (%) | 0 (0.0%)   | 8 (0.4%)      |
| 15-30 days   | 53 (1.4%)     | 46 (1.5%)     | 0 (%) | (n<=5)     | 5 (1.1%)    | 59 (1.6%)     | 49 (2.7%)     | 0 (%) | (n<=5)     | 9 (0.5%)      |
| No prescription  | 253 (6.9%)    | 0 (0.0%)      | 0 (%) | 0 (0.0%)   | 253 (54.2%) | 1,690 (45.0%) | 0 (0.0%)      | 0 (%) | 0 (0.0%)   | 1,690 (88.1%) |

Numbers in parentheses are percentages of total number of patients in the group; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention; IQR, interquartile range; Local hospital, hospital without catheterization laboratory; Main regional hospital, hospital with catheterization laboratory; Tertiary cardiac hospital, university hospital with catheterization laboratory; CABG, coronary artery bypass graft; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs

**Supplementary Table 3** Baseline demographic and clinical characteristics for the 2011 first-time MI population

|   | Patients with PCI (N=3782, 53%) |                       |                     |                    |                  | Patients without PCI (N=3334, 47%) |                       |                     |                   |                   |
|---|---------------------------------|-----------------------|---------------------|--------------------|------------------|------------------------------------|-----------------------|---------------------|-------------------|-------------------|
|   | All patients<br>n=3782          | Clopidogrel<br>n=2204 | Ticagrelor<br>n=766 | Prasugrel<br>n=408 | No DAPT<br>n=404 | All patients<br>n=3334             | Clopidogrel<br>n=1327 | Ticagrelor<br>n=332 | Prasugrel<br>n=30 | No DAPT<br>n=1645 |
| Age [median (IQR)]                          | 65 (55 - 74)                    | 66 (56 - 75)          | 64 (55 - 73)        | 61 (51 - 67)       | 67 (59 - 74.5)   | 74 (63 - 83)                       | 75 (65 - 84)          | 72 (62 - 81.5)      | 60.5 (51 - 67)    | 73 (63 - 83)      |
| Males                                       | 2,744 (72.6%)                   | 1,590 (72.1%)         | 554 (72.3%)         | 320 (78.4%)        | 280 (69.3%)      | 1,803 (54.1%)                      | 708 (53.4%)           | 179 (53.9%)         | 20 (66.7%)        | 896 (54.5%)       |
| <b>Type of hospital (at index MI event)</b> |                                 |                       |                     |                    |                  |                                    |                       |                     |                   |                   |
| Local hospital                              | 906 (24.0%)                     | 590 (26.8%)           | 157 (20.5%)         | 50 (12.3%)         | 109 (27.0%)      | 1,354 (40.6%)                      | 520 (39.2%)           | 96 (28.9%)          | 5 (16.7%)         | 733 (44.6%)       |
| Main regional hospital                      | 1,409 (37.3%)                   | 781 (35.4%)           | 315 (41.1%)         | 171 (41.9%)        | 142 (35.1%)      | 1,132 (34.0%)                      | 497 (37.5%)           | 162 (48.8%)         | 15 (50.0%)        | 458 (27.8%)       |
| Tertiary cardiac hospital                   | 1,467 (38.8%)                   | 833 (37.8%)           | 294 (38.4%)         | 187 (45.8%)        | 153 (37.9%)      | 848 (25.4%)                        | 310 (23.4%)           | 74 (22.3%)          | 10 (33.3%)        | 454 (27.6%)       |
| <b>Procedures (at index event)</b>          |                                 |                       |                     |                    |                  |                                    |                       |                     |                   |                   |
| CABG  | 86 (2.3%)                       | 47 (2.1%)             | 8 (1.0%)            | (n<=5)             | 29 (7.2%)        | 449 (13.5%)                        | 169 (12.7%)           | 35 (10.5%)          | (n<=5)            | 242 (14.7%)       |
| Angiography                                 | 3,712 (98.1%)                   | 2,168 (98.4%)         | 746 (97.4%)         | 399 (97.8%)        | 399 (98.8%)      | 1,882 (56.4%)                      | 779 (58.7%)           | 226 (68.1%)         | 18 (60.0%)        | 859 (52.2%)       |
| <b>Previous diagnoses</b>                   |                                 |                       |                     |                    |                  |                                    |                       |                     |                   |                   |
| Heart failure                               | 89 (2.4%)                       | 49 (2.2%)             | 17 (2.2%)           | (n<=5)             | 19 (4.7%)        | 288 (8.6%)                         | 110 (8.3%)            | 15 (4.5%)           | (n<=5)            | 161 (9.8%)        |
| Ischaemic heart disease                     | 276 (7.3%)                      | 134 (6.1%)            | 63 (8.2%)           | 20 (4.9%)          | 59 (14.6%)       | 395 (11.8%)                        | 149 (11.2%)           | 35 (10.5%)          | 6 (20.0%)         | 205 (12.5%)       |
| Unstable angina                             | 57 (1.5%)                       | 25 (1.1%)             | 14 (1.8%)           | 6 (1.5%)           | 12 (3.0%)        | 66 (2.0%)                          | 23 (1.7%)             | (n<=5)              | (n<=5)            | 37 (2.2%)         |
| Peripheral arterial disease                 | 130 (3.4%)                      | 70 (3.2%)             | 24 (3.1%)           | 14 (3.4%)          | 22 (5.4%)        | 231 (6.9%)                         | 96 (7.2%)             | 21 (6.3%)           | (n<=5)            | 113 (6.9%)        |
| Stroke total                                | 131 (3.5%)                      | 75 (3.4%)             | 28 (3.7%)           | (n<=5)             | 24 (5.9%)        | 276 (8.3%)                         | 126 (9.5%)            | 26 (7.8%)           | 0 (0.0%)          | 124 (7.5%)        |
| Non-ischaemic stroke                        | 13 (0.3%)                       | 12 (0.5%)             | 0 (0.0%)            | 0 (0.0%)           | (n<=5)           | 14 (0.4%)                          | 5 (0.4%)              | (n<=5)              | 0 (0.0%)          | 7 (0.4%)          |
| Ischaemic stroke                            | 123 (3.3%)                      | 68 (3.1%)             | 28 (3.7%)           | (n<=5)             | 23 (5.7%)        | 269 (8.1%)                         | 124 (9.3%)            | 25 (7.5%)           | 0 (0.0%)          | 120 (7.3%)        |
| Atrial fibrillation                         | 144 (3.8%)                      | 71 (3.2%)             | 25 (3.3%)           | 7 (1.7%)           | 41 (10.1%)       | 353 (10.6%)                        | 116 (8.7%)            | 24 (7.2%)           | 0 (0.0%)          | 213 (12.9%)       |
| Chronic renal dysfunction                   | 25 (0.7%)                       | 12 (0.5%)             | 6 (0.8%)            | (n<=5)             | 6 (1.5%)         | 37 (1.1%)                          | 12 (0.9%)             | (n<=5)              | 0 (0.0%)          | 24 (1.5%)         |
| Diabetes mellitus                           | 507 (13.4%)                     | 284 (12.9%)           | 102 (13.3%)         | 40 (9.8%)          | 81 (20.0%)       | 641 (19.2%)                        | 262 (19.7%)           | 66 (19.9%)          | 5 (16.7%)         | 308 (18.7%)       |
| Major bleeding                              | 91 (2.4%)                       | 56 (2.5%)             | 18 (2.3%)           | (n<=5)             | 14 (3.5%)        | 180 (5.4%)                         | 64 (4.8%)             | 11 (3.3%)           | 0 (0.0%)          | 105 (6.4%)        |
| Liver disease                               | (n<=5)                          | (n<=5)                | 0 (0.0%)            | 0 (0.0%)           | (n<=5)           | 7 (0.2%)                           | (n<=5)                | 0 (0.0%)            | 0 (0.0%)          | 6 (0.4%)          |
| Coagulation disorders                       | 10 (0.3%)                       | 5 (0.2%)              | (n<=5)              | 0 (0.0%)           | (n<=5)           | 17 (0.5%)                          | (n<=5)                | (n<=5)              | 0 (0.0%)          | 12 (0.7%)         |
| Cancer                                      | 236 (6.2%)                      | 144 (6.5%)            | 37 (4.8%)           | 20 (4.9%)          | 35 (8.7%)        | 345 (10.3%)                        | 135 (10.2%)           | 35 (10.5%)          | 0 (0.0%)          | 175 (10.6%)       |
| <b>Drug use at discharge</b>                |                                 |                       |                     |                    |                  |                                    |                       |                     |                   |                   |
| Total number of drugs [median (IQR)]        | 3 (1 - 6)                       | 3 (1 - 6)             | 3 (1 - 7)           | 2 (0 - 5)          | 5 (2 - 8)        | 6 (3 - 10)                         | 6 (3 - 10)            | 5 (2.5 - 9)         | 4.5 (1 - 7)       | 7 (3 - 11)        |
| ACE-inhibitors and ARB                      | 2,087 (55.2%)                   | 1,243 (56.4%)         | 403 (52.6%)         | 214 (52.5%)        | 227 (56.2%)      | 1,897 (56.9%)                      | 785 (59.2%)           | 195 (58.7%)         | 17 (56.7%)        | 900 (54.7%)       |
| Acetyl salicylic acid                       | 3,600 (95.2%)                   | 2,204 (100.0%)        | 766 (100.0%)        | 408 (100.0%)       | 222 (55.0%)      | 2,728 (81.8%)                      | 1,327 (100.0%)        | 332 (100.0%)        | 30 (100.0%)       | 1,039 (63.2%)     |
| Betablocker                                 | 3,311 (87.5%)                   | 1,940 (88.0%)         | 676 (88.3%)         | 368 (90.2%)        | 327 (80.9%)      | 2,398 (71.9%)                      | 1,068 (80.5%)         | 267 (80.4%)         | 27 (90.0%)        | 1,036 (63.0%)     |
| Calcium-channel blocker                     | 859 (22.7%)                     | 492 (22.3%)           | 186 (24.3%)         | 59 (14.5%)         | 122 (30.2%)      | 1,091 (32.7%)                      | 464 (35.0%)           | 95 (28.6%)          | 10 (33.3%)        | 522 (31.7%)       |

|  |               |               |             |             |             |               |               |             |            |               |
|--|---------------|---------------|-------------|-------------|-------------|---------------|---------------|-------------|------------|---------------|
| Oral antidiabetics and insulin                                     | 467 (12.3%)   | 266 (12.1%)   | 97 (12.7%)  | 35 (8.6%)   | 69 (17.1%)  | 561 (16.8%)   | 235 (17.7%)   | 62 (18.7%)  | 5 (16.7%)  | 259 (15.7%)   |
| Proton pump inhibitors   | 1,077 (28.5%) | 632 (28.7%)   | 255 (33.3%) | 70 (17.2%)  | 120 (29.7%) | 1,324 (39.7%) | 487 (36.7%)   | 121 (36.4%) | 6 (20.0%)  | 710 (43.2%)   |
| Statins  | 3,593 (95.0%) | 2,112 (95.8%) | 739 (96.5%) | 399 (97.8%) | 343 (84.9%) | 2,336 (70.1%) | 1,076 (81.1%) | 277 (83.4%) | 29 (96.7%) | 954 (58.0%)   |
| Anticoagulant  | 238 (6.3%)    | 121 (5.5%)    | 35 (4.6%)   | 16 (3.9%)   | 66 (16.3%)  | 447 (13.4%)   | 102 (7.7%)    | 30 (9.0%)   | (n<=5)     | 314 (19.1%)   |
| NSAIDs   | 658 (17.4%)   | 382 (17.3%)   | 142 (18.5%) | 60 (14.7%)  | 74 (18.3%)  | 646 (19.4%)   | 256 (19.3%)   | 71 (21.4%)  | (n<=5)     | 315 (19.1%)   |
| <b>Time until P2Y<sub>12</sub> antagonist prescription claimed</b> |               |               |             |             |             |               |               |             |            |               |
| Prior to MI  | 148 (3.9%)    | 90 (4.1%)     | 24 (3.1%)   | 15 (3.7%)   | 19 (4.7%)   | 192 (5.8%)    | 116 (8.7%)    | 19 (5.7%)   | 5 (16.7%)  | 52 (3.2%)     |
| 1-7 days   | 3,389 (89.6%) | 2,085 (94.6%) | 727 (94.9%) | 387 (94.9%) | 190 (47.0%) | 1,689 (50.7%) | 1,150 (86.7%) | 308 (92.8%) | 23 (76.7%) | 208 (12.6%)   |
| 8-14 days  | 28 (0.7%)     | 13 (0.6%)     | 9 (1.2%)    | (n<=5)      | (n<=5)      | 38 (1.1%)     | 30 (2.3%)     | (n<=5)      | 0 (0.0%)   | (n<=5)        |
| 15-30 days   | 29 (0.8%)     | 16 (0.7%)     | 6 (0.8%)    | (n<=5)      | (n<=5)      | 40 (1.2%)     | 31 (2.3%)     | (n<=5)      | (n<=5)     | 6 (0.4%)      |
| No prescription  | 188 (5.0%)    | 0 (0.0%)      | 0 (0.0%)    | 0 (0.0%)    | 188 (46.5%) | 1,375 (41.2%) | 0 (0.0%)      | 0 (0.0%)    | 0 (0.0%)   | 1,375 (83.6%) |

Numbers in parentheses are percentages of total number of patients in the group; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention; IQR, interquartile range; Local hospital, hospital without catheterization laboratory; Main regional hospital, hospital with catheterization laboratory; Tertiary cardiac hospital, university hospital with catheterization laboratory; CABG, coronary artery bypass graft; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs.